Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR).

Clinical Trial Description

Laryngopharyngeal reflux (LPR) is a disorder caused by acid-induced damage to the larynx and pharynx (voice box and throat). The standard care for persons with this disorder is treatment with highly potent anti-acid medications (proton pump inhibitors - Prevacid is one of these. NExium, Aciphex and Prilosec are others). These medications are currently approved by the FDA for the treatment of gastroesophageal reflux disease (GERD). Although the use of these medications in persons with LPR is widely accepted and sanctioned, this research is being done because these medications are not currently approved by the FDA for this use. The purpose of this study is to determine whether treatment with twice-daily Lansoprazole 30mg (Prevacid 30mg) and behavioral modifications for reflux is superior to treatment with behavioral modifications for reflux alone in the treatment of laryngopharyngeal reflux (LPR). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00864396
Study type	Interventional
Source	University of California, Davis
Contact
Status	Completed
Phase	Phase 1
Start date	July 2005
Completion date	May 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06205446` - Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction	N/A
Completed	`NCT02552966` - Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin	N/A
Completed	`NCT01450748` - Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux	Phase 3
Recruiting	`NCT04827355` - Reflux Band in Laryngopharyngeal Reflux	N/A
Not yet recruiting	`NCT03455803` - Effect of CPAP Therapy on LPR Among Patients With OSAS	N/A
Withdrawn	`NCT02530879` - Comparison of Voice Therapy and Antireflex Therapy in LPR	Phase 4
Completed	`NCT01854970` - Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux	N/A
Completed	`NCT00321503` - Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)	N/A
Terminated	`NCT01317472` - The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux	N/A
Completed	`NCT01880892` - Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy	N/A
Completed	`NCT02183961` - Three Methods Used in the Diagnosis of EER in Children With OME	N/A
Not yet recruiting	`NCT01328652` - Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy	Phase 4
Not yet recruiting	`NCT04383262` - Lexiva for the Treatment of LPR	Phase 3
Recruiting	`NCT04984304` - Individualized Diagnosis and Treatment of Extraesophageal Reflux in Patients With Chronic Cough	N/A
Withdrawn	`NCT03463395` - Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux	N/A
Completed	`NCT03619811` - Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease	N/A
Recruiting	`NCT05879029` - Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD	Phase 4
Recruiting	`NCT05204303` - LPR Fluorescence Pilot
Terminated	`NCT01777854` - Anti-reflux Control to Decrease Post Tonsillectomy Pain	Phase 4
Withdrawn	`NCT01308502` - A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux	Phase 4